SCHEMBL12665331

SCHEMBL12665331

CC(C)Cc1cc(-c2ccc(-c3ccc(CCC(=O)O)cc3CC(C)C)cc2C(C)C)ccc1CCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.56
MDM2 Q00987 1/20 0.56
BCL2L1 Q07817 3/20 0.56
MCL1 Q07820 2/20 0.56
S1PR1 P21453 3/20 0.45
FFAR1 O14842 5/20 0.42
BCL2L11 O43521 1/20 0.41
BAK1 Q16611 1/20 0.41
PDE1A P54750 2/20 0.39
PDE1B Q01064 2/20 0.39
PDE1C Q14123 2/20 0.39
FFAR4 Q5NUL3 5/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
S1PR3 Q99500 1/20 0.37
DPP4 P27487 1/20 0.37
PTGER1 P34995 1/20 0.36
PTGER4 P35408 1/20 0.36
PTGER3 P43115 1/20 0.36
PTGER2 P43116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14066685 0.91 TP53 (0.51) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL4651407 0.86 BCL2L1 (0.76) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL14347478 0.84 BCL2L1 (0.68) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL14066645 0.83 TP53 (0.75) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL14347954 0.80 TP53 (0.70) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL14066551 0.79 TP53 (0.37) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL13343696 0.77 TP53 (0.48) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL14066558 0.73 PDE1A (0.65) TP53MDM2BCL2L1MCL1FFAR1
SCHEMBL14347691 0.73 BCL2L1 (0.71) TP53MDM2BCL2L1MCL1S1PR1
SCHEMBL5340223 0.72 GABRA1 (0.46) TP53MDM2BCL2L1MCL1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288335-B2 ApoE analogs and methods for their use Cognosei, Inc. (US) 2012-10-16 US disclosed
US-7947645-B2 APO E analogs and methods for their use COGNOSCI, INC. (US) 2011-05-24 US disclosed
US-20090042783-A1 APO E ANALOGS AND METHODS FOR THEIR USE CORNERSTONE BIOSCIENCES, INC. 2009-02-12 US disclosed
EP-1408986-B1 PROTEOMIMETIC COMPOUNDS AND METHODS UNIV YALE (US) 2008-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042783-A1 APO E ANALOGS AND METHODS FOR THEIR USE APOB, APOL1, APP TP53 3815/4885MDM2 3672/4885BCL2L1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.